News | Structural Heart | March 14, 2023

New Online Tool to Help Clinicians Calculate Patient Risk Associated with Mitral Valve Repair Surgery

The Society of Thoracic Surgeons (STS) has developed and launched a new risk calculator to estimate the risk of mitral valve repair for patients with mitral valve prolapse and degenerative primary mitral regurgitation, or primary MR.

Getty Images


March 14, 2023 —  The Society of Thoracic Surgeons (STS) has developed and launched a new risk calculator to estimate the risk of mitral valve repair for patients with mitral valve prolapse and degenerative primary mitral regurgitation, or primary MR. 

STS’s Risk Calculator for Surgical Repair of Primary Mitral Regurgitation enables providers to enter a patient’s demographics, risk factors such as smoking and diabetes, lab results, and details about their heart disease and surgical history. The Calculator then produces a result that provides statistically robust objective estimates of the patient’s individual risk for death or surgical complications. 

“Risk estimation for surgical intervention is an essential component of a heart team’s shared decision-making process,” said STS President Thomas MacGillivray, MD. “This important new STS Risk Calculator will make a significant difference for patients with mitral valve prolapse and regurgitation as it will give their cardiologists and surgeons an objective method to help determine the optimal course of treatment tailored to the individual.” 

The STS National Database accounts for over 97% of all heart operations performed in the United States. The new calculator utilizes contemporary and procedure-specific data from the STS Adult Cardiac Surgery Database that are most representative of the surgeries being performed today. 

“Recently published studies demonstrated that in the vast majority of patients with primary MR due to mitral valve prolapse, the risk of mortality associated with mitral valve repair surgery is less than 1%. These new data, specific for these patients, has informed the new STS risk calculator,” Dr. MacGillivray said. 

STS is a global leader in risk model development as a means to improve quality and patient care. Risk calculators, such as this new tool for primary MR, help inform multidisciplinary medical providers as they choose the optimal care for their patients. 

The STS National Database is one of largest clinical registries in healthcare, including more than 8 million records and over 97% of cardiothoracic operations performed in the United States. 

More detailed information about the Risk Calculator for Surgical Repair of Primary Mitral Regurgitation is available in The Annals of Thoracic Surgery: https://www.annalsthoracicsurgery.org/article/S0003-4975(22)01611-3/fulltext 

Click here to access the Calculator: Risk Calculator for Surgical Repair of Primary Mitral Regurgitation | STS 


Related Content

News | Structural Heart

March 5, 2023 — In patients with heart failure and a poorly functioning heart valve, a minimally invasive procedure ...

Home March 05, 2023
Home
News | Structural Heart

March 4, 2023 — Abbott announced late-breaking data for the TriClip transcatheter edge-to-edge repair (TEER) system, a ...

Home March 04, 2023
Home
News | Structural Heart

February 6, 2023 — University of Virginia researchers and their collaborators have identified genes that play key roles ...

Home February 06, 2023
Home
News | Structural Heart

January 19, 2023 — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the company's latest ...

Home January 19, 2023
Home
News | Structural Heart

December 13, 2022 — Edwards Lifesciences Corporation announced that one-year results on patients treated in the single ...

Home December 13, 2022
Home
News | Structural Heart

December 2, 2022 — Boston Scientific Corporation has announced the first results from the ACURATE neo2 Post Market ...

Home December 02, 2022
Home
News | Structural Heart

November 30, 2022 — Boston Scientific Corporation has announced the first results from the ACURATE neo2 Post Market ...

Home November 30, 2022
Home
News | Structural Heart

November 30, 2022 — Medtronic’s newest generation self-expanding, transcatheter aortic valve replacement (TAVR) system ...

Home November 30, 2022
Home
News | Structural Heart

September 26, 2022 — Medtronic plc, a global leader in medical technology, announced U.S. Food and Drug Administration ...

Home September 26, 2022
Home
News | Structural Heart

September 20, 2022 — Results of the first randomized controlled trial to directly compare two contemporary transcatheter ...

Home September 20, 2022
Home
Subscribe Now